Show
Sort by
-
Serum vitamin C concentration is low in peripheral arterial disease and is associated with inflammation and severity of atherosclerosis (with comment: Vitamin C depletion linked to inflammation in peripheral artery disease. M. Larkin Lancet, 357, 2001, 1184).
-
Haptoglobin polymorphism and peripheral arterial occlusive disease
-
Is angiotensin-converting enzyme I/D polymorphism involved in cardiovascular complications in essential hypertension ?
-
Vitamin D binding protein polymorphism and polymetabolic syndrome in essential hypertension
-
Haptoglobin polymorphism and hypertension in the elderly
-
Angiotensin-I converting enzyme (ACE) gene polymorphism and the erythrocyte sodium-lithium countertransport in hypertension.
-
Genetic polymorphisms and erythrocyte sodium-lithium countertransport in essential hypertension
-
Refractory hypertension is associated with haptoglobin 2-2 phenotype
-
Sodium-lithium countertransport and vitamin D binding protein polymorphism in essential arterial hypertension.
-
MN blood-group, a genetic-marker for essential arterial-hypertension in young-adults.
-
MN blood group phenotype, a genetic risk factor for early onset of essential arterial hypertension
-
MN blood group, a genetic marker for essential arterial hypertension
-
Coagulation system activation and increase of D-dimers levels in peripheral arterial occlusive disease
-
MN bloodgroup, a genetic marker for arterial pressure height and body mass index in treated essential hypertension
-
Haptoglobin polymorphism and peripheral arterial occlusive disease
-
MN blood group, a genetic marker for essential arterial hypertension.
-
MN blood group, a genetic marker for arterial pressure height and body mass index in treated essential hypertension
-
MN blood group, a genetic marker for arterial blood pressure height and body mass index in treated essential hypertension.
-
Flow cytometric detection of platelet response to ADP in peripheral arterial occlusive disease after treadmill exercise
-
Calculation of acute myocardial infarction size making use of cumulative myoglobin release in serum